Skip to main content
NCBI home page
Heart logoLink to Heart
. 1999 Sep;82(3):307–311. doi: 10.1136/hrt.82.3.307

Predicting the effect of D,L-sotalol on ventricular tachycardia inducibility from the RR variability response

B Brembilla-Perrot 1, P Houriez 1, O Claudon 1, J Preiss 1, D Beurrier 1
PMCID: PMC1729166  PMID: 10455080

Abstract

AIM—To find a rapid way of identifying non-responders to D,L-sotalol in patients with ventricular tachycardia.
METHODS—Programmed ventricular stimulation and RR variability were studied in the control state and 10 days after treatment with 160 to 320 mg of D,L-sotalol in 36 consecutive patients with ventricular tachycardia.
RESULTS—In 14 patients (group I) D,L-sotalol suppressed ventricular tachycardia inducibility. In 22 patients (group II) sustained ventricular tachycardia remained inducible during D,L-sotalol treatment. The ventricular tachycardia rate was slowed in eight patients and unchanged or accelerated in 14. At baseline, heart rate variability was similar in both groups. During treatment with D,L-sotalol, variables reflecting parasympathetic activity (pNN50, rMSSD, and high frequency amplitude (HF)) increased in both groups: HF increased from (mean (SD)) 75 (68) to 146 (134) in group I (p < 0.05) and from 60 (49) to 125 (79) in group II (p < 0.05). Other variables were unchanged in group I. In group II, the variables associated with sympathetic activity (coefficient of variance (CV), ratio of low frequency amplitude (LF) to HF) decreased significantly: CV decreased from 13 (4) to 9 (2) (p < 0.001) and LF/HF from 4.74 (3.02) to 3.00 (2.02) (p < 0.05).
CONCLUSIONS—The β blocking effect of D,L-sotalol produced a significant improvement over control values in indices of parasympathetic tone in all treated patients. However, the heart rate variability indices related to sympathetic activity were decreased only in non-responders. This effect of D,L-sotalol on heart rate variability could help detect non-responders to the drug and avoid an electrophysiological study.


Keywords: sotalol; ventricular tachycardia; heart rate variability

Full Text

The Full Text of this article is available as a PDF (80.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Antimisiaris M., Sarma J. S., Schoenbaum M. P., Sharma P. P., Venkataraman K., Singh B. N. Effects of amiodarone on the circadian rhythm and power spectral changes of heart rate and QT interval: significance for the control of sudden cardiac death. Am Heart J. 1994 Nov;128(5):884–891. doi: 10.1016/0002-8703(94)90584-3. [DOI] [PubMed] [Google Scholar]
  2. Appel M. L., Berger R. D., Saul J. P., Smith J. M., Cohen R. J. Beat to beat variability in cardiovascular variables: noise or music? J Am Coll Cardiol. 1989 Nov 1;14(5):1139–1148. doi: 10.1016/0735-1097(89)90408-7. [DOI] [PubMed] [Google Scholar]
  3. Bigger J. T., Jr, Fleiss J. L., Steinman R. C., Rolnitzky L. M., Kleiger R. E., Rottman J. N. Frequency domain measures of heart period variability and mortality after myocardial infarction. Circulation. 1992 Jan;85(1):164–171. doi: 10.1161/01.cir.85.1.164. [DOI] [PubMed] [Google Scholar]
  4. Bigger J. T., Jr, Rolnitzky L. M., Steinman R. C., Fleiss J. L. Predicting mortality after myocardial infarction from the response of RR variability to antiarrhythmic drug therapy. J Am Coll Cardiol. 1994 Mar 1;23(3):733–740. doi: 10.1016/0735-1097(94)90761-7. [DOI] [PubMed] [Google Scholar]
  5. Brembilla-Perrot B., de la Chaise A. T., Briançon S., Suty-Selton C., Beurrier D., Martin N., Thiel B., Louis P., Danchin N. Programmed ventricular stimulation in survivors of acute myocardial infarction: long-term follow-up. Int J Cardiol. 1995 Mar 24;49(1):55–65. doi: 10.1016/0167-5273(95)02273-y. [DOI] [PubMed] [Google Scholar]
  6. Brodsky M. A., Chough S. P., Allen B. J., Capparelli E. V., Orlov M. V., Caudillo G. Adjuvant metoprolol improves efficacy of class I antiarrhythmic drugs in patients with inducible sustained monomorphic ventricular tachycardia. Am Heart J. 1992 Sep;124(3):629–635. doi: 10.1016/0002-8703(92)90270-6. [DOI] [PubMed] [Google Scholar]
  7. Böcker D., Block M., Borggrefe M., Breithardt G. Defibrillators are superior to antiarrhythmic drugs in the treatment of ventricular tachyarrhythmias. Eur Heart J. 1997 Jan;18(1):26–30. doi: 10.1093/oxfordjournals.eurheartj.a015113. [DOI] [PubMed] [Google Scholar]
  8. Böcker D., Haverkamp W., Block M., Borggrefe M., Hammel D., Breithardt G. Comparison of d,l-sotalol and implantable defibrillators for treatment of sustained ventricular tachycardia or fibrillation in patients with coronary artery disease. Circulation. 1996 Jul 15;94(2):151–157. doi: 10.1161/01.cir.94.2.151. [DOI] [PubMed] [Google Scholar]
  9. Graboys T. B., Lown B., Podrid P. J., DeSilva R. Long-term survival of patients with malignant ventricular arrhythmia treated with antiarrhythmic drugs. Am J Cardiol. 1982 Sep;50(3):437–443. doi: 10.1016/0002-9149(82)90307-1. [DOI] [PubMed] [Google Scholar]
  10. Julian D. G., Camm A. J., Frangin G., Janse M. J., Munoz A., Schwartz P. J., Simon P. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet. 1997 Mar 8;349(9053):667–674. doi: 10.1016/s0140-6736(96)09145-3. [DOI] [PubMed] [Google Scholar]
  11. Julian D. G., Prescott R. J., Jackson F. S., Szekely P. Controlled trial of sotalol for one year after myocardial infarction. Lancet. 1982 May 22;1(8282):1142–1147. doi: 10.1016/s0140-6736(82)92225-5. [DOI] [PubMed] [Google Scholar]
  12. Kleiger R. E., Miller J. P., Bigger J. T., Jr, Moss A. J. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol. 1987 Feb 1;59(4):256–262. doi: 10.1016/0002-9149(87)90795-8. [DOI] [PubMed] [Google Scholar]
  13. Kontopoulos A. G., Athyros V. G., Papageorgiou A. A., Papadopoulos G. V., Avramidis M. J., Boudoulas H. Effect of quinapril or metoprolol on heart rate variability in post-myocardial infarction patients. Am J Cardiol. 1996 Feb 1;77(4):242–246. doi: 10.1016/s0002-9149(97)89386-1. [DOI] [PubMed] [Google Scholar]
  14. Lombardi F., Torzillo D., Sandrone G., Dalla Vecchia L., Finocchiaro M. L., Bernasconi R., Cappiello E. Beta-blocking effect of propafenone based on spectral analysis of heart rate variability. Am J Cardiol. 1992 Oct 15;70(11):1028–1034. doi: 10.1016/0002-9149(92)90355-3. [DOI] [PubMed] [Google Scholar]
  15. Malik M., Farrell T., Cripps T., Camm A. J. Heart rate variability in relation to prognosis after myocardial infarction: selection of optimal processing techniques. Eur Heart J. 1989 Dec;10(12):1060–1074. doi: 10.1093/oxfordjournals.eurheartj.a059428. [DOI] [PubMed] [Google Scholar]
  16. Mølgaard H., Mickley H., Pless P., Bjerregaard P., Møller M. Effects of metoprolol on heart rate variability in survivors of acute myocardial infarction. Am J Cardiol. 1993 Jun 1;71(15):1357–1359. doi: 10.1016/0002-9149(93)90555-q. [DOI] [PubMed] [Google Scholar]
  17. Pousset F., Copie X., Lechat P., Jaillon P., Boissel J. P., Hetzel M., Fillette F., Remme W., Guize L., Le Heuzey J. Y. Effects of bisoprolol on heart rate variability in heart failure. Am J Cardiol. 1996 Mar 15;77(8):612–617. doi: 10.1016/s0002-9149(97)89316-2. [DOI] [PubMed] [Google Scholar]
  18. Sandrone G., Mortara A., Torzillo D., La Rovere M. T., Malliani A., Lombardi F. Effects of beta blockers (atenolol or metoprolol) on heart rate variability after acute myocardial infarction. Am J Cardiol. 1994 Aug 15;74(4):340–345. doi: 10.1016/0002-9149(94)90400-6. [DOI] [PubMed] [Google Scholar]
  19. Vaishnav S., Stevenson R., Marchant B., Lagi K., Ranjadayalan K., Timmis A. D. Relation between heart rate variability early after acute myocardial infarction and long-term mortality. Am J Cardiol. 1994 Apr 1;73(9):653–657. doi: 10.1016/0002-9149(94)90928-8. [DOI] [PubMed] [Google Scholar]
  20. Zuanetti G., Latini R., Neilson J. M., Schwartz P. J., Ewing D. J. Heart rate variability in patients with ventricular arrhythmias: effect of antiarrhythmic drugs. Antiarrhythmic Drug Evaluation Group (ADEG). J Am Coll Cardiol. 1991 Mar 1;17(3):604–612. doi: 10.1016/s0735-1097(10)80172-x. [DOI] [PubMed] [Google Scholar]

Articles from Heart are provided here courtesy of BMJ Publishing Group

RESOURCES